John J McCarthy1, Martin H Leamon, Neil H Willits, Ruth Salo. 1. From the Bi-Valley Medical Clinic, Carmichael, CA (JJM); and Departments of Psychiatry and Behavioral Sciences (JJM, MHL, RS) and Statistics (NHW), University of California, Davis.
Abstract
OBJECTIVES: To evaluate the effects of a multiple daily dose methadone regimen in pregnancy on neonatal outcomes. METHODS: Although methadone maintenance has been the standard for the treatment of opioid dependence in pregnancy, there is no consensus on proper dosing. Single daily dosing is the most common strategy. Because of accelerated metabolism of methadone in pregnancy, this regimen may expose mother and fetus to daily episodes of withdrawal and possibly contribute to more severe Neonatal Abstinence Syndrome (NAS). This study reports on a protocol that increased both methadone dose and dose frequency in response to maternal reports of withdrawal. RESULTS: Treatment of NAS was needed in 29% of neonates, compared to a published rate of 60% to 80%. The mean methadone dose was 152 mg at delivery, divided into 2 to 6 doses per day. Ninety-two percent of mothers were free of illicit drug use at delivery. There was no relationship between methadone dose and treatment of NAS. Female babies had a treatment rate of 16% versus 38% for male babies. Beyond abstinence symptoms, cohort outcomes in terms of gestational age, birth weight, prematurity, Caesarian sections, and breastfeeding equaled or approximated US population norms. CONCLUSIONS: The protocol was associated with low rates of treatment of NAS and high rates of maternal recovery. High rates of treatment for NAS reported in methadone-exposed neonates might relate in part to iatrogenic factors and be reduced through the use of divided daily doses and protocols that minimize maternal withdrawal.
OBJECTIVES: To evaluate the effects of a multiple daily dose methadone regimen in pregnancy on neonatal outcomes. METHODS: Although methadone maintenance has been the standard for the treatment of opioid dependence in pregnancy, there is no consensus on proper dosing. Single daily dosing is the most common strategy. Because of accelerated metabolism of methadone in pregnancy, this regimen may expose mother and fetus to daily episodes of withdrawal and possibly contribute to more severe Neonatal Abstinence Syndrome (NAS). This study reports on a protocol that increased both methadone dose and dose frequency in response to maternal reports of withdrawal. RESULTS: Treatment of NAS was needed in 29% of neonates, compared to a published rate of 60% to 80%. The mean methadone dose was 152 mg at delivery, divided into 2 to 6 doses per day. Ninety-two percent of mothers were free of illicit drug use at delivery. There was no relationship between methadone dose and treatment of NAS. Female babies had a treatment rate of 16% versus 38% for male babies. Beyond abstinence symptoms, cohort outcomes in terms of gestational age, birth weight, prematurity, Caesarian sections, and breastfeeding equaled or approximated US population norms. CONCLUSIONS: The protocol was associated with low rates of treatment of NAS and high rates of maternal recovery. High rates of treatment for NAS reported in methadone-exposed neonates might relate in part to iatrogenic factors and be reduced through the use of divided daily doses and protocols that minimize maternal withdrawal.
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Davida M Schiff; Elisha M Wachman; Barbara Philipp; Kathleen Joseph; Hira Shrestha; Elsie M Taveras; Margaret G K Parker Journal: Breastfeed Med Date: 2018-04-09 Impact factor: 1.817
Authors: John J McCarthy; Hendree E Jones; Mishka Terplan; Vania P Rudolf; Melinda Campopiano von Klimo Journal: J Addict Med Date: 2021-04-01 Impact factor: 3.702
Authors: Shikhar Shrestha; Melissa H Roberts; Jessie R Maxwell; Lawrence M Leeman; Ludmila N Bakhireva Journal: Neurotoxicol Teratol Date: 2021-03-23 Impact factor: 4.071
Authors: Victoria J Monnelly; Devasuda Anblagan; Alan Quigley; Manuel Blesa Cabez; E Sarah Cooper; Helen Mactier; Scott I Semple; Mark E Bastin; James P Boardman Journal: Neuroimage Clin Date: 2017-12-24 Impact factor: 4.881